FDA Approves Novel ' Tissue Agnostic ' Cancer Drug FDA Approves Novel ' Tissue Agnostic ' Cancer Drug

Larotrectinib targets a key genetic driver that occurs in multiple types of cancer, rather than a specific tumor type.FDA Approvals
Source: Medscape General Surgery Headlines - Category: Surgery Tags: Hematology-Oncology News Alert Source Type: news